Texas Permanent School Fund Boosts Position in Haemonetics Co. (NYSE:HAE)

Texas Permanent School Fund raised its stake in Haemonetics Co. (NYSE:HAEGet Rating) by 2.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 36,943 shares of the medical instruments supplier’s stock after acquiring an additional 707 shares during the period. Texas Permanent School Fund’s holdings in Haemonetics were worth $2,408,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HAE. Mutual of America Capital Management LLC raised its stake in Haemonetics by 2.0% during the 1st quarter. Mutual of America Capital Management LLC now owns 46,613 shares of the medical instruments supplier’s stock worth $2,947,000 after acquiring an additional 906 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Haemonetics by 61.6% during the first quarter. Envestnet Asset Management Inc. now owns 24,716 shares of the medical instruments supplier’s stock worth $1,563,000 after purchasing an additional 9,417 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Haemonetics by 527.3% in the 1st quarter. Victory Capital Management Inc. now owns 41,516 shares of the medical instruments supplier’s stock valued at $2,426,000 after purchasing an additional 34,898 shares during the last quarter. State of Michigan Retirement System boosted its position in shares of Haemonetics by 1.7% in the 1st quarter. State of Michigan Retirement System now owns 12,974 shares of the medical instruments supplier’s stock valued at $820,000 after purchasing an additional 218 shares during the period. Finally, Royce & Associates LP grew its stake in Haemonetics by 6.9% during the 1st quarter. Royce & Associates LP now owns 757,244 shares of the medical instruments supplier’s stock worth $47,873,000 after buying an additional 49,136 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Mizuho boosted their price objective on Haemonetics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, November 8th. Raymond James increased their price target on shares of Haemonetics from $88.00 to $100.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 8th. StockNews.com initiated coverage on shares of Haemonetics in a research note on Wednesday, October 12th. They issued a “buy” rating on the stock. Citigroup increased their target price on shares of Haemonetics from $80.00 to $88.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 8th. Finally, TheStreet upgraded Haemonetics from a “c+” rating to a “b” rating in a research report on Monday, November 7th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $96.17.

Insider Buying and Selling

In other Haemonetics news, EVP Michelle L. Basil sold 11,448 shares of Haemonetics stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $78.36, for a total value of $897,065.28. Following the sale, the executive vice president now owns 32,635 shares of the company’s stock, valued at approximately $2,557,278.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Haemonetics news, EVP Michelle L. Basil sold 33,798 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $77.89, for a total value of $2,632,526.22. Following the completion of the transaction, the executive vice president now owns 35,395 shares in the company, valued at $2,756,916.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michelle L. Basil sold 11,448 shares of the business’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $78.36, for a total transaction of $897,065.28. Following the sale, the executive vice president now owns 32,635 shares in the company, valued at $2,557,278.60. The disclosure for this sale can be found here. Insiders sold 45,713 shares of company stock valued at $3,566,256 over the last ninety days. Corporate insiders own 1.65% of the company’s stock.

Haemonetics Stock Down 2.0 %

Shares of Haemonetics stock opened at $77.63 on Tuesday. The company has a market cap of $3.93 billion, a P/E ratio of 46.77 and a beta of 0.40. The firm has a fifty day moving average of $78.06 and a two-hundred day moving average of $69.74. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.27 and a current ratio of 2.73. Haemonetics Co. has a one year low of $43.50 and a one year high of $86.48.

Haemonetics Profile

(Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEGet Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.